These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30392396)

  • 1. 21st-Century Oncology Drug Safety via New-Age Regulatory Standards and Practices.
    Pitts PJ; Le Louet H; Katz G
    Ther Innov Regul Sci; 2019 Sep; 53(5):701-705. PubMed ID: 30392396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the Valley of Death to the Crossroads of Opportunity: A Discussion of Evolving Benefit/Risk Evaluation Standards.
    Pitts PJ; Brady P
    Ther Innov Regul Sci; 2018 Sep; 52(5):531-536. PubMed ID: 29763344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing Drug Safety Through Prospective Pharmacovigilance.
    Pitts PJ; Le Louet H
    Ther Innov Regul Sci; 2018 Jul; 52(4):400-402. PubMed ID: 29714580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance: a science or fielding emergencies?
    Evans SJ
    Stat Med; 2000 Dec; 19(23):3199-209. PubMed ID: 11113954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory pathways in the European Union.
    Kohler M
    MAbs; 2011; 3(3):241-2. PubMed ID: 21487236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC).
    Fujiwara Y; Kobayashi K
    Crit Rev Oncol Hematol; 2002 May; 42(2):145-55. PubMed ID: 12007972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 21st century pharmacovigilance: efforts, roles, and responsibilities.
    Pitts PJ; Louet HL; Moride Y; Conti RM
    Lancet Oncol; 2016 Nov; 17(11):e486-e492. PubMed ID: 27819246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 15. Oncology drug development: United States Food and Drug Administration perspective.
    Hirschfeld S; Pazdur R
    Crit Rev Oncol Hematol; 2002 May; 42(2):137-43. PubMed ID: 12007971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
    Sugay J
    Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk minimization activities of centrally authorized products in the EU: a descriptive study.
    Zomerdijk IM; Sayed-Tabatabaei FA; Trifirò G; Blackburn SC; Sturkenboom MC; Straus SM
    Drug Saf; 2012 Apr; 35(4):299-314. PubMed ID: 22339506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
    J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.